MedTrace Logo

Efficacy and Safety of Oxantel Pamoate in Children Infected With Trichuris Trichiura

NCT06720259 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 163

Last updated 2025-06-08

No results posted yet for this study

Summary

This study aims to provide evidence on the efficacy, safety and acceptability of the new, chewable formulation of oxantel pamoate administered as a single dose or multiple doses, compared to mebendazole in children infected with T. trichiura. This study will involve children aged 2-12 years, since an infection with T. trichiura occurs often in children.

Conditions

  • Trichuris Trichiura; Infection
  • Hookworm Infection
  • Ascaris Lumbricoides Infection

Interventions

DRUG

Oxantel Pamoate

Tablets containing 250 mg oxantel pamoate

DRUG

Mebendazole

Tablets containing 500 mg mebendazole

Sponsors & Collaborators

  • Public Health Laboratory Ivo de Carneri

    collaborator OTHER

  • Jennifer Keiser

    lead OTHER

Principal Investigators

  • Jennifer Keiser, PhD · Swiss Tropical & Public Health Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-16
Primary Completion
2025-05-28
Completion
2025-05-28

Countries

  • Tanzania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06720259 on ClinicalTrials.gov